- |||||||||| budesonide / Generic mfg., loperamide / Generic mfg.
Journal: Diagnosis and Pharmacological Management of Microscopic Colitis in Geriatric Care. (Pubmed Central) - Jan 17, 2024
Consequently, other therapeutic options (e.g., bismuth subsalicylate, biologics, loperamide, bile acid sequestrants, and thiopurines) recommended by available guidelines may be prescribed. Herein, clinically meaningful data is provided based on the latest evidence that may aid in reaching a diagnosis and establishing rational therapy in geriatric care to control symptoms and enhance the quality of life for those affected.
- |||||||||| Filspari (sparsentan) / Travere Therap, CSL Behring
Journal: Nephrology: what's new in 2023 (Pubmed Central) - Jan 17, 2024
Sodium bicarbonate does not seem to protect renal function in renal transplant patients. SGLT2 inhibitors may have a beneficial effect in these patients in terms of nephroprotection.
- |||||||||| dexamethasone / Generic mfg., sirolimus / Generic mfg.
Journal: Effects of Horse Meat Hydrolysate on Oxidative Stress, Proinflammatory Cytokines, and the Ubiquitin-Proteasomal System of C2C12 Cells. (Pubmed Central) - Jan 17, 2024
Additionally, A4<3kDa activated protein synthesis-related proteins through the protein kinase B/mechanistic target of rapamycin pathway, while decreasing the expression of activity and degradation-related proteins, such as Forkhead box O3, muscle RING finger protein-1, and Atrogin-1 in dexamethasone-treated C2C12 myotubes. Therefore, the natural material A4<3kDa has the potential ofprotecting against muscle atrophy, while further in vivo study is needed.
- |||||||||| Empliciti (elotuzumab) / AbbVie, BMS, iberdomide (CC-220) / BMS
Enrollment status, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 17, 2024
P1, N=6, Enrolling by invitation,
Therefore, the natural material A4<3kDa has the potential ofprotecting against muscle atrophy, while further in vivo study is needed. Recruiting --> Enrolling by invitation | N=31 --> 6 | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2024
- |||||||||| hydrocortisone / Generic mfg., epinephrine / Generic mfg.
Trial completion date, Trial primary completion date: Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest. (clinicaltrials.gov) - Jan 17, 2024
P=N/A, N=191, Not yet recruiting,
Not yet recruiting --> Recruiting Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
- |||||||||| Tarpeyo (budesonide) / Calliditas, Stada
Journal: IgA nephropathy (Pubmed Central) - Jan 17, 2024
Nefecon (encapsulated budesonide) is the first specific drug licensed for treatment of high risk IgAN patients. A
- |||||||||| Agamree (vamorolone) / Santhera
Review, Journal: Vamorolone: First Approval. (Pubmed Central) - Jan 17, 2024
Vamorolone was approved in October 2023 for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older in the USA and received a positive opinion in the EU in October 2023 for the treatment of DMD in patients 4 years of age and older. This article summarizes the milestones in the development of vamorolone leading to this first approval for DMD.
- |||||||||| dexamethasone injection / Generic mfg., ibuprofen / Generic mfg.
Trial completion date, Trial termination, Trial primary completion date: Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity (clinicaltrials.gov) - Jan 17, 2024
P3, N=215, Terminated,
This article summarizes the milestones in the development of vamorolone leading to this first approval for DMD. Trial completion date: Jun 2024 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; slow recruitment
- |||||||||| Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
New P3 trial, Combination therapy: MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov) - Jan 17, 2024
P3, N=795, Not yet recruiting,
- |||||||||| Promacta (eltrombopag) / Novartis
Enrollment closed, Enrollment change, Immunomodulating: iROM2: Immunomodulation With Eltrombopag in ITP (clinicaltrials.gov) - Jan 17, 2024
P2, N=2, Active, not recruiting,
Trial completion date: Jun 2024 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; slow recruitment Recruiting --> Active, not recruiting | N=24 --> 2
- |||||||||| dexamethasone / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: Duration of Analgesia in Bier Block for Patients Undergoing Hand Surgery (clinicaltrials.gov) - Jan 17, 2024
P=N/A, N=75, Not yet recruiting,
Recruiting --> Active, not recruiting | N=24 --> 2 Trial completion date: Jan 2024 --> Jul 2024 | Trial primary completion date: Jan 2024 --> Jul 2024
- |||||||||| dexamethasone / Generic mfg.
Journal: Differential susceptibility of male and female germ cells to glucocorticoid-mediated signaling. (Pubmed Central) - Jan 16, 2024
In contrast, our studies revealed that the male germline is susceptible to glucocorticoid-mediated signaling, specifically by regulating RNA splicing within the spermatogonia, although this does not abrogate fertility. Together, our work suggests a sexually dimorphic function for GR in the germline, and represents an important step towards understanding the mechanisms by which stress can modulate the transmission of genetic information through the germline.
- |||||||||| dexamethasone / Generic mfg.
Journal: Immediate implantation of ultrafine fiber slow-release system based on cell electrospinning to induce osteogenesis of mesenchymal stem cells. (Pubmed Central) - Jan 16, 2024
Utilizing dual-nozzle and cell electrospinning techniques, the system encapsulates L-ascorbic acid-2-phosphate magnesium (ASP), ?-glycerophosphate sodium and dexamethasone (DEX) within the fibers, ensuring sustained osteogenic differentiation...Notably, immediate implantation into New Zealand White rabbits led to significant new bone formation within 8?weeks. These findings underscore the system's potential for immediate in vivo implantation without prior in vitro induction, marking a promising advancement in bone tissue engineering.
- |||||||||| betamethasone / Generic mfg.
Trial primary completion date: KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP (clinicaltrials.gov) - Jan 16, 2024
P3, N=700, Recruiting,
These findings underscore the system's potential for immediate in vivo implantation without prior in vitro induction, marking a promising advancement in bone tissue engineering. Trial primary completion date: Dec 2023 --> Apr 2024
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Journal: Patient With Rigidity and Fasciculations. (Pubmed Central) - Jan 15, 2024
Anti-IgLON5 disease has progressive course and protean clinical presentations, representative, in our patient, for overlapping signs and symptoms of neuromuscular hyperexcitability and rigidity. Identification of rare phenotypes is important because prompt recognition and treatment can improve prognosis.
- |||||||||| dexamethasone / Generic mfg., morphine sulphate / Generic mfg.
Retrospective data, Review, Journal: High dose glucocorticoids for treatment of postoperative pain: A systematic review of the literature and meta-analysis. (Pubmed Central) - Jan 15, 2024
High doses of glucocorticoids are one of the many possible tools available in multimodal postoperative analgesia, possibly reducing opioids consumption and recurrence of PONV but with no relevant effects in terms of reduction of postoperative VAS score. Available data show a safe therapeutic profile, without increase adverse events.
- |||||||||| dexamethasone / Generic mfg., cisplatin / Generic mfg., capecitabine / Generic mfg.
Journal: Steroidal saponins from the roots of Paris verticillata and their anti-proliferative and anti-inflammatory activities. (Pubmed Central) - Jan 15, 2024
The anti-proliferative activities of all compounds against LN229, HepG2, MDA-MB-231 and 4T1 cell lines were evaluated using the CCK8 assay with cisplatin or capecitabine as the positive control. The anti-inflammatory activities of all compounds were measured by inhibition of LPS-induced NO release from BV2 cell lines, with dexamethasone as the positive control.
- |||||||||| Darzalex (daratumumab) / J&J
Journal: Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX. (Pubmed Central) - Jan 15, 2024
P3
In the phase 3 CASTOR and POLLUX studies, daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS), regardless of cytogenetic risk, and achieved higher rates of complete response or better (?CR) and minimal residual disease (MRD) negativity vs that with Vd/Rd alone in relapsed/refractory MM. See updated abstract in uploaded manuscript.
- |||||||||| indomethacin / Generic mfg., hydrocortisone / Generic mfg.
Journal: Risk factors and epidemiology of spontaneous intestinal perforation among infants born at 22-24 weeks' gestational age. (Pubmed Central) - Jan 15, 2024
"Triple therapy" with dexamethasone, metoclopramide, and octreotide for management of nonsurgical MBO in this small sample size appears safe and well tolerated however a diagnosis of inoperable MBO remains associated with poor prognosis and death within months. Antenatal magnesium exposure, antenatal indomethacin exposure, postnatal hydrocortisone exposure, postnatal indomethacin exposure, and weight loss ?15% were associated with SIP.
- |||||||||| fluocinolone acetonide / Generic mfg., hydroquinone / Generic mfg.
Journal: Best Practices in the Treatment of Melasma with a Focus on Patients with Skin of Color. (Pubmed Central) - Jan 15, 2024
Antenatal magnesium exposure, antenatal indomethacin exposure, postnatal hydrocortisone exposure, postnatal indomethacin exposure, and weight loss ?15% were associated with SIP. Melasma can be challenging to treat, particularly in patients with skin of color, and our recommendations for best practices for patients in the United States are an important step toward standardizing care.
- |||||||||| dexamethasone / Generic mfg.
Journal: Five Years Follow-up of Opsoclonus-Myoclonus-Ataxia Syndrome-Associated Neurogenic Tumors in Children. (Pubmed Central) - Jan 15, 2024
Melasma can be challenging to treat, particularly in patients with skin of color, and our recommendations for best practices for patients in the United States are an important step toward standardizing care. ?In tumor-related cases, alternating use of corticosteroid and IVIG for suppression of autoimmunity as the OMAS protocol, total excision of the tumor as soon as possible, and chemotherapeutics in selected patients seem to be related to resolution of acute problems, long-term sequelae, and severity.
- |||||||||| dexamethasone / Generic mfg.
Journal, Adverse events: Skin Anti-Inflammatory Potential with Reduced Side Effects of Novel Glucocorticoid Receptor Agonists. (Pubmed Central) - Jan 15, 2024
Of note, these beneficial actions were not associated with GC-related atrophic effects: treatments of primary keratinocytes and fibroblasts with DE.303 and KL.202 did not induce, contrarily to dexamethasone-a known potent GC-alterations in extracellular matrix components and lipid synthesis, thus confirming their safety profile. These data provide the basis for evaluating these compounds as effective alternatives to the currently used GCs in managing inflammatory skin diseases.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Drug-Drug Interactions Between COVID-19 Treatments and Psychotropic Medications: An Updated Study. (Pubmed Central) - Jan 15, 2024
Although our case series provides some evidence of effectiveness and safety, further controlled studies on a larger scale are necessary, particularly to compare this intervention with the use of corticosteroid injections alone. We discuss the implications of our findings on appropriate treatment plan selection by healthcare providers for patients taking select antipsychotics, antidepressants, mood stabilizers, and benzodiazepines while receiving COVID-19 treatments.
- |||||||||| dexamethasone / Generic mfg., acyclovir / Generic mfg.
Journal, Immunomodulating: Adjunctive Intravenous Immunoglobulin and (Pubmed Central) - Jan 14, 2024
Low-dose dexamethasone in the THA perioperative period can effectively reduce inflammatory marker levels, pain, nausea, postoperative fatigue, opioid analgesic use, and shorten PLOS without increasing complications. CASE REPORT We describe the case of a young male with clinically and radiographically severe HSV-1 encephalitis diagnosed by PCR of cerebrospinal fluid (CSF), who demonstrated immediate improvement upon treatment with intravenous immunoglobulin (IVIG, 0.5 g/kg daily
|
